Contact
searchSearch
HMP Global
Login
Quiz

Zanzalintinib Plus Atezolizumab in Relapsed/Refractory Metastatic Colorectal Cancer

Edited by 
Emily Estrada
04/01/2026
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.

Related Content

News
Dose-Reduced Chemotherapy Expands Treatment Options for Frail Patients with Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ELDERLY trial demonstrated that dose-reduced chemotherapy regimens show clinical activity with a manageable safety profile in elderly and frail elderly patients with metastatic colorectal cancer.
Results from the phase 2 ELDERLY trial demonstrated that dose-reduced chemotherapy regimens show clinical activity with a manageable safety profile in elderly and frail elderly patients with metastatic colorectal cancer.
Results from the phase 2 ELDERLY...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
Quiz
Tucatinib Plus Trastuzumab for HER2-Posititive Metastatic Colorectal Cancer
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology

Recent News

News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
News
Ruxolitinib Plus Venetoclax Demonstrates Safe but Limited Clinical Activity in Relapsed/Refractory AML
03/31/2026
Emily Estrada
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter,...
03/31/2026
Oncology
News
Low-Dose CT Screening Reduces Lung Cancer Mortality in a Non–Risk-Based Population
03/26/2026
Emily Estrada
According to a prospective analysis of patients enrolled in the Lung-Care project, low-dose CT screening significantly reduces lung cancer mortality in a non–risk-based population.
According to a prospective analysis of patients enrolled in the Lung-Care project, low-dose CT screening significantly reduces lung cancer mortality in a non–risk-based population.
According to a prospective...
03/26/2026
Oncology
News
TTFields Plus Atezolizumab and Chemotherapy Improves Disease Control in Metastatic Pancreatic Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2...
03/26/2026
Oncology
News
Ceralasertib Plus Durvalumab Does Not Improve Outcomes in Advanced Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Final results from the phase 3 LATIFY trial demonstrated that ceralasertib plus durvalumab did not improve survival outcomes compared with docetaxel in advanced non-small cell lung cancer.
Final results from the phase 3 LATIFY trial demonstrated that ceralasertib plus durvalumab did not improve survival outcomes compared with docetaxel in advanced non-small cell lung cancer.
Final results from the phase 3...
03/26/2026
Oncology
News
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Updated results from the phase 3 OptiTROP-Lung03 trial demonstrate that sacituzumab tirumotecan significantly improves survival outcomes compared with docetaxel in previously treated patients with EGFR-mutated non-small cell lung cancer.
Updated results from the phase 3 OptiTROP-Lung03 trial demonstrate that sacituzumab tirumotecan significantly improves survival outcomes compared with docetaxel in previously treated patients with EGFR-mutated non-small cell lung cancer.
Updated results from the phase 3...
03/26/2026
Oncology
News
Osimertinib Plus Local Consolidative Therapy Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 NorthStar trial demonstrate that adding local consolidative therapy to osimertinib significantly improves outcomes in EGFR-mutated non-small cell lung cancer.
Results from the phase 2 NorthStar trial demonstrate that adding local consolidative therapy to osimertinib significantly improves outcomes in EGFR-mutated non-small cell lung cancer.
Results from the phase 2...
03/26/2026
Oncology
News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the...
03/25/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use